Mary K. Olson

Tulane University

Professor

Department of Economics

306 Tilton Hall

New Orleans, LA 70118

United States

SCHOLARLY PAPERS

12

DOWNLOADS

0

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (12)

1.

New Clinical Information and Physician Prescribing: How Do Pediatric Labeling Changes Affect Prescribing to Children?

Health Economics. 30(1), January 2021, 144-164. https://doi.org/10.1002/hec.4182
Posted: 25 Feb 2021
Mary K. Olson and Nina Yin
Tulane University and Central University of Finance and Economics (CUFE) - China Center for Human Capital and Labor Market Research

Abstract:

Loading...

FDA regulation, innovation policy, market incentives, pediatric exclusivity, pharmaceuticals

2.

Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity

American Journal of Health Economics, vol. 4, issue 3, Summer 2018, pp. 321-357
Posted: 29 Aug 2018
Mary K. Olson and Nina Yin
Tulane University and Central University of Finance and Economics (CUFE) - China Center for Human Capital and Labor Market Research

Abstract:

Loading...

Innovation Policy, Market Incentives, Pharmaceuticals, Pediatric Exclusivity, FDA Regulation

3.

Firm Characteristics and the Speed of FDA Approval

Journal of Economics and Management Strategy, Vol. 6, No. 2, Summer 1997: 377-401
Posted: 26 Jul 2014
Mary K. Olson
Tulane University

Abstract:

Loading...

FDA regulation, new drug approval, drug review speed

4.

Eliminating the U.S. Drug Lag: Implications for Drug Safety

Journal of Risk and Uncertainty, Vol. 47, Issue 1, pp. 1-30, August 2013
Posted: 10 Aug 2013
Mary K. Olson
Tulane University

Abstract:

Loading...

drug safety, drug approval, drug lag

5.

The Risk We Bear: The Effects of Review Speed and Industry User Fees on New Drug Safety

Journal of Health Economics, Vol. 27, No. 2, 2008
Posted: 21 Mar 2008
Mary K. Olson
Tulane University

Abstract:

Loading...

new-drug review, drug safety, pharmaceutical regulation, FDA, PDUFA

6.

Are Novel Drugs More Risky for Patients than Less Novel Drugs?

Posted: 22 Nov 2004
Mary K. Olson
Tulane University

Abstract:

Loading...

New-drug approvals, drug novelty, drug safety, pharmaceutical regulation, FDA

7.

Managing Delegation in the Fda: Reducing Delay in New-Drug Review

Posted: 14 Dec 2003
Mary K. Olson
Tulane University

Abstract:

Loading...

8.

Pharmaceutical Policy Change and the Safety of New Drugs

Posted: 21 Jul 2003
Mary K. Olson
Tulane University

Abstract:

Loading...

pharmaceutical policy, FDA regulation, new-drug safety

Abstract:

Loading...

10.

Agency Rulemaking, Political Influences, Regulation, and Industry Compliance

Posted: 21 Sep 1999
Mary K. Olson
Tulane University

Abstract:

Loading...

11.

Regulatory Agency Discretion Among Competing Industries: Inside the Fda

JOURNAL OF LAW, ECONOMICS, AND ORGANIZATION, Vol 11 No 2, Fall 1995)
Posted: 25 Aug 1998
Mary K. Olson
Tulane University

Abstract:

Loading...

12.

Substitution in Regulatory Agencies: Fda Enforcement Alternatives

Journal of Law, Economics, and Organization, Vol. 12, No. 2, Fall 1996.
Posted: 18 Aug 1996
Mary K. Olson
Tulane University

Abstract:

Loading...